Dr. Eggener’s research and clinical interests focus on improving the management and outcomes for patients with localized prostate cancer with specific emphasis on active surveillance, focal therapy and optimizing surgical outcomes. He has published extensively on prostate cancer with 75 peer-reviewed publications and multiple on PSA screening, surgery, prostate imaging, active surveillance or focal therapy for prostate cancer. He is on the editorial board of four journals, including Prostate Cancer and Prostatic Diseases.
Memorial Sloan-Kettering Cancer Center
New York
Urologic oncology fellowship
Northwestern Memorial Hospital
Chicago
General and urologic surgery internship and residency
Standford University School of Medicine
California
MD
MXene and prostate cancer: is there promising news?
MXene and prostate cancer: is there promising news? Nanomedicine (Lond). 2025 May; 20(9):1001-1014.
PMID: 40235346
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial.
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J Urol. 2025 May; 213(5):590-599.
PMID: 40202133
Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial.
Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. J Urol. 2025 Apr 09; 101097JU0000000000004561.
PMID: 40203124
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025 04; 23(4).
PMID: 40203876
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling.
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling. J Natl Cancer Inst. 2025 Apr 01; 117(4):685-691.
PMID: 39565901
New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review.
New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review. Prostate Cancer Prostatic Dis. 2025 Mar 27.
PMID: 40140552
When is prostate cancer really cancer?
When is prostate cancer really cancer? J Natl Cancer Inst. 2025 Mar 01; 117(3):402-405.
PMID: 39350309
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. Nat Genet. 2025 Feb; 57(2):334-344.
PMID: 39930085
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Feb 20; 43(6):748-758.
PMID: 39787437
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment. Radiol Imaging Cancer. 2025 Jan; 7(1):e240156.
PMID: 39836080